Transcend Therapeutics Presents New Data At ASCP Demonstrating Improvements In Functioning And Sleep-Related Symptoms in PTSD Patients Treated with TSND-201 (Methylone)

TSND-201 for the Treatment for PTSD: Functional and Global Improvements from the Open-Label Portion of the IMPACT-1 Study (T36)

TSND-201 for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open-label Portion of the IMPACT-1 Study (W45)

TSND-201, a rapid-acting treatment for PTSD and other Central Nervous System (CNS) disorders (T89)

Transcend Therapeutics announces publication of new preclinical data demonstrating TSND-201 (methylone) is a rapid-acting neuroplastogen with fewer off-target effects than MDMA

Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA